quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·29d
PRRelease
Neurocrine Biosciences Inc. logo

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

NBIX· Neurocrine Biosciences Inc.
Health Care
Original source

Companies

  • NBIX
    Neurocrine Biosciences Inc.
    Health Care

Recent analyst ratings

  • Feb 24UpdateWolfe Research$160.00
  • Jan 8UpdateMorgan Stanley$175.00
  • Oct 21UpdateCitigroup$175.00
  • Jul 21UpdateTruist$163.00
  • Jul 10UpdateGoldman$182.00
  • Apr 15UpdateNeedham$138.00

Related

  • PR1d
    Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
  • SEC8d
    SEC Form DEFA14A filed by Neurocrine Biosciences Inc.
  • SEC8d
    SEC Form DEF 14A filed by Neurocrine Biosciences Inc.
  • PR9d
    Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
  • PR10d
    Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
  • SEC18d
    Neurocrine Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR18d
    Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022